Journal of Hepatology
Volume 53, Issue 1 , Pages 191-198 , July 2010

Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials

  • Mieke M.H. Lamers

      Affiliations

    • Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Martijn G.H. van Oijen

      Affiliations

    • Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Martine Pronk

      Affiliations

    • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • Joost P.H. Drenth

      Affiliations

    • Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, code 455, 6500 HB Nijmegen, The Netherlands. Tel.: +31 24 3614760; fax: +31 24 3540103.
    web address

References 

  1. Czaja AJ. Current concepts in autoimmune hepatitis. Ann Hepatol. 2005;4:6–24
  2. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002;6:635–647
  3. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938
  4. Krawitt EL. Clinical features and management of autoimmune hepatitis. World J Gastroenterol. 2008;14:3301–3305
  5. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176
  6. Teufel A, Galle PR, Kanzler S. Update on autoimmune hepatitis. World J Gastroenterol. 2009;15:1035–1041
  7. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159–185
  8. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833
  9. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and Azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737
  10. Czaja AJ, Freese DK. Diagnosis and treatment of Autoimmune Hepatitis. Hepatology. 2002;36:479–497
  11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  12. Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomized controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet. 1985;1:668–670
  13. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988;8:781–784
  14. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology. 1999;30:1381–1386
  15. Czaja AJ, Wang KK, Shiels MT, Katzmann JA. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J Hepatol. 1993;17:180–186
  16. Hegarty JE, Nouri Aria KT, Eddleston AL, Williams R. Controlled trial of a thymic hormone extract (Thymostimulin) in ‘autoimmune’ chronic active hepatitis. Gut. 1984;25:279–283
  17. Tage-Jensen U, Schlichting P, Aldershvile J, et al. Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification. Liver. 1982;2:95–103
  18. Summerskill WHJ, Korman GK, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876–883
  19. Stern RB, Wilkinson SP, Howorth PJN, Williams R. Controlled trial of synthetic d-penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut. 1977;18:19–22
  20. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology. 2001;120:1502–1517
  21. Manns MP, Bahr MJ, Woynarowski M, et al. Budesonide 3mg tid is superior to prednisone in combination with azathioprine in the treatment of autoimmune hepatitis. J Hepatol 2008;48:S369–70(S2) [Abstract].
  22. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide 3 mg bid in combination with azathioprine as maintenance treatment of autoimmune hepatitis – final results of a large multicenter international trial. Hepatology. 2008;48:376A(S)–377A(S)[Abstract]
  23. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958–963
  24. Czaja AJ. Treatment of Autoimmune Hepatitis. Semin Liver Dis. 2002;22:365–378
  25. Czaja AJ. Treatment challenges and investigational opportunities in Autoimmune Hepatitis. Hepatology. 2005;41:207–215

PII: S0168-8278(10)00189-3

doi: 10.1016/j.jhep.2010.01.037

Journal of Hepatology
Volume 53, Issue 1 , Pages 191-198 , July 2010

Article Tools

* Image Usage & Resolution